{"url_path":"/sec/spro/8-k/2026-06-22/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-277506-index.html","accession_number":"0001193125-26-277506","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-277506-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":104,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nOn June 17, 2026, the Company issued a press release announcing that the FDA has granted approval for Utebzi (tebipenem pivoxil), an oral antibiotic for the treatment of cUTIs, including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment option. This is the first and only oral carbapenem antibiotic approved for these patients. This approval is a result of GSK’s development and exclusive global licensing agreement (excluding select Asian territories) with the Company. FDA approval was received in advance of FDA-assigned Prescription Drug User Fee Act (“PDUFA”) date of June 18, 2026."}